Get the Stockscreener App
63.96
0.13%
0.08
After Hours:
60.09
-3.87
-6.05%
Royalty Pharma Plc stock is traded at $63.96, with a volume of 3.37M.
It is up +0.13% in the last 24 hours and up +11.27% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$63.88
Open:
$63.55
24h Volume:
3.37M
Relative Volume:
1.09
Market Cap:
$28.48B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
33.50
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
+5.11%
1M Performance:
+11.27%
6M Performance:
+34.85%
1Y Performance:
+73.33%
1-Day Range:
$63.43
$64.38
1-Week Range:
$60.39
$64.38
52-Week Range:
$34.08
$64.38
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
63.96 | 26.97B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma PLC $RPRX Position Increased by TD Waterhouse Canada Inc. - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Navigating Growth with a 16.5% Revenue Surge - DirectorsTalk Interviews
Royalty Pharma Updates on Novartis' HORIZON Trial Results - Intellectia AI
Royalty Pharma expects modest return despite pelacarsen trial failure - Investing.com
Royalty Pharma Announces Novartis HORIZON Pelacarsen Trial Results and Updates Return Outlook on Ionis Funding Agreement - Quiver Quantitative
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - pmg-ky3.com
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - GlobeNewswire Inc.
Trading the Move, Not the Narrative: (RPRX) Edition - news.stocktradersdaily.com
Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma - Seeking Alpha
Royalty Pharma stock hits all-time high at 62.48 USD By Investing.com - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $7.84 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighWhat's Next? - MarketBeat
Royalty Pharma stock hits all-time high at 62.48 USD - Investing.com
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 6.41% Potential Upside - DirectorsTalk Interviews
Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX - MarketBeat
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Odyssean LLC Acquires 21,401 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Strong Buy Ratings and Promising Growth in the Biotech Sector - DirectorsTalk Interviews
Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal? - Sahm
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to "Strong-Buy" - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
RPHC5824520 Bond Profile — Key Metrics - TradingView
30,000 Shares in Royalty Pharma PLC $RPRX Purchased by Monetta Financial Services Inc. - MarketBeat
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity - Kalkine Media
Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma stock hits all-time high at 60.44 USD - Investing.com
Royalty Pharma stock hits all-time high at 60.44 USD By Investing.com - Investing.com Nigeria
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025. - marketscreener.com
Commerzbank Aktiengesellschaft FI Invests $1.20 Million in Royalty Pharma PLC $RPRX - MarketBeat
How Investors Are Reacting To Royalty Pharma (RPRX) Buying Rusfertide Royalties From Zealand Pharma - simplywall.st
Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale - Stock Titan
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares - Investing.com South Africa
Pablo Legorreta's 101.8M-share Royalty Pharma (NASDAQ: RPRX) stake updated - Stock Titan
Royalty Pharma (RPRX) CFO sells 11,002 shares in trading plan - Stock Titan
LYNWOOD PRICE CAPITAL MANAGEMENT LP's Royalty Pharma PLC(RPRX) Holding History - GuruFocus
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 10.49% Potential Upside - DirectorsTalk Interviews
S&CO Inc. Buys Shares of 358,302 Royalty Pharma PLC $RPRX - MarketBeat
Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years - Benzinga
Royalty Pharma (RPRX) Following Mixed Earnings Still Looks Close To Fair Value - Sahm
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story? - Yahoo Finance
Royalty Pharma (RPRX) holder TPC RP EPA1 LLC eyes 11,002-share stock sale - Stock Titan
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug - Benzinga
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Hits Perfect Technical Rating with Breakout Setup - ChartMill
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million - The Manila Times
Royalty Pharma (RPRX) files to potentially sell 11.9M Class A shares - Stock Titan
RPRX (RPRX) investor files to sell 125,000 Class A shares on NASDAQ - Stock Titan
Zealand gains $100M in funding from Royalty Pharma (RPRX:NASDAQ) - Seeking Alpha
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):